ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
In the Phase III SANOVO trial, Orpathys extended PFS to 24.8 months in IHC 3+ NSCLC, but tolerability may weigh as heavily as efficacy.
Unlock FREE Access to Premium Content
Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.
With a free Pharmaceutical Technology profile, you can:
- Access exclusive analyst commentary and expert insights
- View premium forecasts and data-driven pharmaceutical industry insights
- Stay up to date with pharma news, manufacturing innovation, and regulatory developments
- Receive alerts when new premium content is published
Unlock free access
Already have an account? Login herePowered by
